These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 18084669)

  • 1. [Indium-111-DTPA-phenyl-pentetreotide somatostatin receptors' scintigraphy in the evaluation of patients with suspected gastro-entero-pancreatic tumors. Comparison with computerized tomography].
    Gerasimou GP; Aggelopoulou T; Papanastasiou E; Konidari-Dedousi E; Prousalidis I; Psarrakos K; Siountas A; Molybda E; Gotzamani-Psarrakou A
    Hell J Nucl Med; 2007; 10(3):209-14. PubMed ID: 18084669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors.
    Schillaci O; Spanu A; Scopinaro F; Falchi A; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
    J Nucl Med; 2003 Mar; 44(3):359-68. PubMed ID: 12621001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors.
    Namwongprom S; Wong FC; Tateishi U; Kim EE; Boonyaprapa S
    Ann Nucl Med; 2008 May; 22(4):237-43. PubMed ID: 18535873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors.
    Hasegawa S; Kobayashi N; Tokuhisa M; Goto A; Takano S; Takada Y; Kaneta T; Mori R; Matsuyama R; Endo I; Yamanaka S; Nakajima A; Inoue T; Ichikawa Y
    Digestion; 2017; 96(1):13-20. PubMed ID: 28609761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours.
    Chiti A; Fanti S; Savelli G; Romeo A; Bellanova B; Rodari M; van Graafeiland BJ; Monetti N; Bombardieri E
    Eur J Nucl Med; 1998 Oct; 25(10):1396-403. PubMed ID: 9818279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management.
    Jamar F; Fiasse R; Leners N; Pauwels S
    J Nucl Med; 1995 Apr; 36(4):542-9. PubMed ID: 7699439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor scintigraphy with 111In-pentetreotide for endocrine gastroenteropancreatic tumors.
    Joseph K; Stapp J; Reinecke J; Skamel HJ; Höffken H; Neuhaus C; Lenze H; Trautmann ME; Arnold R
    Horm Metab Res Suppl; 1993; 27():28-35. PubMed ID: 8330869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [111In-pentetreotide in the study of tumors expressing somatostatin receptors].
    Mateos Fernández J; Pons Pons F; Fuster Pelfort D; Vidal-Sicart S; Lomeña Caballero F; Herranz García-Romero R
    Rev Esp Med Nucl; 1999 Oct; 18(5):325-30. PubMed ID: 10562660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours.
    Savelli G; Lucignani G; Seregni E; Marchianò A; Serafini G; Aliberti G; Villano C; Maccauro M; Bombardieri E
    Nucl Med Commun; 2004 May; 25(5):445-9. PubMed ID: 15100502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 111In-pentetreotide (somatostatin analogue) scintigraphy as an imaging procedure for endocrine gastro-entero-pancreatic tumors.
    Nauck C; Ivancević V; Emrich D; Creutzfeldt W
    Z Gastroenterol; 1994 Jun; 32(6):323-7. PubMed ID: 7975760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors.
    Schillaci O; Spanu A; Scopinaro F; Falchi A; Corleto V; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
    Int J Oncol; 2003 Dec; 23(6):1687-95. PubMed ID: 14612942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scintigraphic detection of carcinoid tumors with a cost effectiveness analysis.
    Dimitroulopoulos D; Xynopoulos D; Tsamakidis K; Paraskevas E; Zisimopoulos A; Andriotis E; Fotopoulou E; Kontis M; Paraskevas I
    World J Gastroenterol; 2004 Dec; 10(24):3628-33. PubMed ID: 15534919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors.
    Lebtahi R; Cadiot G; Sarda L; Daou D; Faraggi M; Petegnief Y; Mignon M; le Guludec D
    J Nucl Med; 1997 Jun; 38(6):853-8. PubMed ID: 9189129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours.
    Schillaci O; Corleto VD; Annibale B; Scopinaro F; Delle Fave G
    Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S186-9. PubMed ID: 10604127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging of neuroendocrine gastro-entero-pancreatic tumours using radiolabelled somatostatin analogues.
    Chiti A; van Graafeiland BJ; Savelli G; Ferrari L; Seregni E; Castellani MR; Bombardieri E
    Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S190-4. PubMed ID: 10604128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy.
    Lebtahi R; Cadiot G; Delahaye N; Genin R; Daou D; Peker MC; Chosidow D; Faraggi M; Mignon M; Le Guludec D
    J Nucl Med; 1999 Oct; 40(10):1602-8. PubMed ID: 10520698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The scintigraphy of somatostatin receptors in the carcinoid tumor].
    Banzo J; Abós MD; Prats E; Delgado M; Razola P; García S; Gomollón F; García F
    Rev Esp Med Nucl; 2001 Feb; 20(1):11-8. PubMed ID: 11181324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction and diagnosis of bone metastases in well-differentiated gastro-entero-pancreatic endocrine cancer: a prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy.
    Leboulleux S; Dromain C; Vataire AL; Malka D; Aupérin A; Lumbroso J; Duvillard P; Elias D; Hartl DM; De Baere T; Guigay J; Schlumberger M; Ducreux M; Baudin E
    J Clin Endocrinol Metab; 2008 Aug; 93(8):3021-8. PubMed ID: 18522978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours.
    Chiti A; Briganti V; Fanti S; Monetti N; Masi R; Bombardieri E
    Q J Nucl Med; 2000 Mar; 44(1):42-9. PubMed ID: 10932600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy.
    Valli N; Catargi B; Ronci N; Leccia F; Guyot M; Roger P; Ducassou D; Tabarin A
    Thyroid; 1999 Jun; 9(6):583-9. PubMed ID: 10411121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.